In This Article:
GAITHERSBURG, Md., April 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its Chief Scientific Officer (CSO), Tom Chittenden, will be presenting at the Quantum Computing Symposium during the Bio-IT World Conference & Expo in Boston on April 15, 2024. The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.
Chittenden's presentation will explain how quantum methods have been used to decipher complex disease patterns, including analysis of multi-omics cancer data and classification of severe COVID-19 patients. These innovative methods demonstrate the potential to surpass traditional computational models, offering new pathways for understanding complex disease patterns with limited training data sets. This approach not only enhances the precision of medicine but also paves the way for tackling the increasing volume of genomic data in healthcare.
"We are at the forefront of a technological revolution in healthcare, where quantum computing's potential to transform the field of precision medicine is immense," said Chittenden. "The research I will highlight during my presentation is a testament to the synergies between quantum computing and machine learning, offering novel solutions to longstanding challenges in biomedical sciences."
The Quantum Computing Symposium is a premier event for professionals in the pharmaceutical industry, highlighting the revolutionary role of quantum technologies across various sectors, including drug discovery and supply chain management. With over 70% of life science organizations considering the integration of quantum computing into their research and development processes, this event serves as a crucial platform for discussing the future of pharmaceuticals.
About BullFrog AI
BullFrog AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.